In-depth Mendelian randomization analysis of causal factors for coronary artery disease

[1]  B. Neale,et al.  Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases , 2018, Nature Genetics.

[2]  S. Humphries,et al.  Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. , 2016, JAMA cardiology.

[3]  S. Burgess,et al.  Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future , 2016, Current opinion in endocrinology, diabetes, and obesity.

[4]  Dajiang J. Liu,et al.  Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease , 2016, Science.

[5]  M. Schober,et al.  Challenges and Strategies , 2016 .

[6]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[7]  G. Davey Smith,et al.  Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression , 2015, International journal of epidemiology.

[8]  F. Dudbridge,et al.  Re: "Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects". , 2015, American journal of epidemiology.

[9]  S. Thompson,et al.  Multivariable Mendelian Randomization: The Use of Pleiotropic Genetic Variants to Estimate Causal Effects , 2015, American journal of epidemiology.

[10]  Alex P. Reiner,et al.  Mendelian randomization of blood lipids for coronary heart disease , 2014, European heart journal.

[11]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[12]  Benjamin Voight,et al.  MR_predictor: a simulation engine for Mendelian Randomization studies , 2014, Bioinform..

[13]  N. Samani,et al.  Mendelian randomization studies in coronary artery disease. , 2014, European heart journal.

[14]  Tanya M. Teslovich,et al.  Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.

[15]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[16]  A. Butterworth,et al.  Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data , 2013, Genetic epidemiology.

[17]  S. Purcell,et al.  Pleiotropy in complex traits: challenges and strategies , 2013, Nature Reviews Genetics.

[18]  R. Giugliano,et al.  Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study , 2012, The Lancet.

[19]  K. Huber,et al.  Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities , 2012, British journal of pharmacology.

[20]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[21]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[22]  R. Giugliano,et al.  Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy , 2012, Clinical cardiology.

[23]  J. Mckenney,et al.  Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. , 2012, Journal of the American College of Cardiology.

[24]  B. Nordestgaard,et al.  LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. , 2012, The Journal of clinical endocrinology and metabolism.

[25]  Cholesterol Treatment Trialists' Collaborato.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012 .

[26]  P. Toth.  LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals , 2012 .

[27]  B. Nordestgaard,et al.  Abstract 16452: LCAT, HDL Cholesterol and Myocardial Infarction - A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals , 2011 .

[28]  S. Vansteelandt,et al.  Mendelian randomization analysis of case‐control data using structural mean models , 2011, Statistics in medicine.

[29]  N. Sheehan,et al.  Mendelian randomisation: a tool for assessing causality in observational epidemiology. , 2011, Methods in molecular biology.

[30]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[31]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[32]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[33]  S. Lewis.  Mendelian randomization as applied to coronary heart disease, including recent advances incorporating new technology. , 2010, Circulation. Cardiovascular genetics.

[34]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[35]  P. Ridker,et al.  Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genomewide Analysis Among 18 245 Initially Healthy Women From the Women’s Genome Health Study , 2009, Circulation. Cardiovascular genetics.

[36]  M. Tobin,et al.  Mendelian Randomisation and Causal Inference in Observational Epidemiology , 2008, PLoS medicine.

[37]  Jackie A Cooper,et al.  Inflammation, Insulin Resistance, and Diabetes—Mendelian Randomization Using CRP Haplotypes Points Upstream , 2008, PLoS medicine.

[38]  J. Danesh,et al.  Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. , 2008, JAMA.

[39]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[40]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[41]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[42]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[43]  P. Toth.  Low-density lipoprotein reduction in high-risk patients: How low do you go? , 2004, Current atherosclerosis reports.

[44]  P. Toth.  High-Density Lipoprotein and Cardiovascular Risk , 2004, Circulation.

[45]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[47]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[48]  G. Dagenais,et al.  HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. , 2000, Atherosclerosis.

[49]  R. Blumenthal,et al.  Correlates of high HDL cholesterol among women with coronary heart disease. , 2000, American heart journal.

[50]  Alan D. Lopez,et al.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.

[51]  P. Wilson,et al.  High-density lipoprotein, low-density lipoprotein and coronary artery disease. , 1990, The American journal of cardiology.

[52]  D. A. Kenny,et al.  Correlation and Causation , 1937, Wilmott.

[53]  S. Wright.  The Method of Path Coefficients , 1934 .